Effects of 13-cis-retinoic acid on chemoimmunotherapy of metastatic renal cell carcinoma - Results of a retrospective analysis

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 2, 2003, Pages 157-163

  Roigas, Jan ^a   Deger, Serdar ^a   Taymoorian, Kasra ^a   Wille, Andreas H ^a   Johannsen, Manfred ^a   Türk, Ingolf ^a   Schnorr, Dietmar ^a   Loening, Stefan A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

13 CRA; Chemoimmunotherapy; Metastatic renal cell carcinoma

Indexed keywords

ALPHA2A INTERFERON; FLUOROURACIL; INTERLEUKIN 2; ISOTRETINOIN;

ADRENAL METASTASIS; ADULT; AGED; ANOREXIA; ARTICLE; BONE METASTASIS; CALCULATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; FEVER; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MUCOSA INFLAMMATION; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN IRRITATION; STATISTICAL ANALYSIS; VOMITING; WEIGHT REDUCTION;

EID: 0038405098     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803765036328     Document Type: Article

References (20)

1. Mickisch G, Carballido J, Hellsten S, Schulze H, Mensink H. Guidelines on renal cell cancer. Eur Urol 2001;40:252-255.
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-875.
3. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-1492.
4. Atzpodien J, Kirchner H, Hanninen E, Deckert M, Fenner M, Poliwoda H. Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell carcinoma. Eur J Cancer 1993;29A(Suppl.5):6-8.
5. Atzpodien J, Kirchner H, Illiger HJ, Metzner B, Ukena D, Schott H, Funke PJ, Gramatzki M, Jurgenson S, Wandert T, Patzelt T, Reitz M. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: Long-term results of a controlled randomized clinical trial. Br J Cancer 2001;85:1130-1136.
6. Hofmockel G, Langer W, Theiss M, Gruss A, Frohmuller HGW. Chemoimmunotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil. J Urol 1996;156: 18-21.
7. 2 and 5-fluorouracil in the treatment of metastatic renal cell cancer. Eur Urol 1999; 35:204-209.
8. Lopez Hanninen E, Kirchner H, Atzpodien J: Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients. J Urol 1996;155:19-25.
9. Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, Vlamis V, Nanus DM. Interferon alpha-2a and 13-cis-retinoic acid in renal cell carcinoma: Antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995;13:1950-1957.
10. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M. Phase III trial of interferon alpha-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18:2972-2980.
11. Stadler WM, Kuzel T, Dumas M, Vogelzang NJ. Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol 1998;16:1820-1825.
12. Hoffman AD, Engelstein D, Bogenrieder T, Papandreou CN, Steckelman E, Dave A, Motzer RJ, Dmitrovsky E, Albino AP, Nanus DM. Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid. Clin Cancer Res 1996;2:1077-1082.
13. Toma S, Monteghirfo S, Tasso P, Nicolo G, Spadini N, Palumbo R, Molina F. Antiproliferative and synergistic effect of interferon alpha-2a, retinoids and their association in established human cancer cell lines. Cancer Lett 1994;82:209-216.
14. Atzpodien J, Kirchner H, Jonas U, Bergmann, L, Schott H, Heynemann H, Loening SA, Roigas J, Miller SC, Westerhausen H, Helbig H, Bodenstein H, Pomer S, Metzner B, Rebmann U, Hofstetter A, Oberneder R, Wandert T, Patzelt T, Reitz M, and DGCIN-German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group. 13cis-retinoic acid, IFN-alpha2a, IL-2 and chemotherapy in advanced renal cell carcinoma: Results of a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN), submitted to Br J Cancer, 2001. Submitted to N Engl J Med, 2002.
15. Dutcher JP, Logan T, Gordon M, Sosman J, Weiss G, Margolin K, Plasse T, Mier J, Lotze M, Clark J, Atkins M. Phase II trial of interleukin-2, interferon a, and 5-fluorouracil in metastatic renal cell cancer: A cytokine working group study. Clin Cancer Res 2000;6:3442-3450.
16. Allan MJ, Vaughan M, Webb A, Johnston S, Savage P, Eisen T, Bate S, Moore J, Ahern R, Gore ME. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: A phase II study. Br J Cancer 2000;83:980-985.
17. Elias L, Binder M, Mangalik A, Clark D, Morrison B, Altobelli KK, Smith A. Pilot trial of infusional 5-fluorouracil, interleukin-2, and subcutaneous interferon-α for advanced renal cell carcinoma. Am J Clin Oncol 1999;22:156-161.
18. Negrier S, Caty A, Lesimple T, Douillard J-Y, Escudier B, Rossi J-F, Viens P, Gomez F. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alpha with or without fluorouracil. J Clin Oncol 2000;18: 4009-4015.
19. Ravaud A, Audhuy B, Gomez F, Escudier B, Lesimple T, Chevreau C, Douillard J-Y, Caty A, Geoffrois L, Ferrero J-M, Linassier C, Drevon M, Negrier S. Subcutaneous interleukin-2, interferon alpha-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: A multicenter phase II trial. J Clin Oncol 1998;16:2728-2732.
20. Atzpodien J, Kirchner H, Duensing S, Lopez Hanninen E, Franzke A, Buer J, Probst M, Anton P, Poliwoda H. Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. World J Urol 1995;13:174-177.